AI x Oncology & Gene Editing
AI meets DNA: Oncology & Gene Editing
Oncology and gene editing are no longer emerging fields, they are at an inflection point.
AI-driven single-cell analysis, CRISPR variants beyond Cas9, and programmable recombinases are moving from proof-of-concept to clinical and industrial application. These technologies are not only redefining therapeutic paradigms in cancer, but also expanding into agriculture and synthetic biology.
This evening convenes founders and investors at the frontier, to examine how these innovations translate from the lab bench into platforms and products that can reshape industries:
7:00 – 7:30 | Panel 1 — AI × Oncology
Discussion between Hedi Ben Brahim (OneBioscience), Pierre Manceron (Raidium) and Thaïs Walter (assistant professor @Université Paris Cité)
7:30 – 8:00 | Panel 2 — Gene Editing
Discussion between David Del Bourgo (Whitelab Genomics), Jonathan Naccache (BrinkTx) and Xavier Olessa-Daragon (associate Professor of Biological Engineering).
8:00 – 9:30 | Networking
Continue the conversation over drinks and connect with founders, researchers, and investors.
📅 When: Thursday, October 30, 2025
📍 Where: PC'up, ESPCI Paris (Paris 5th)
🔥 Spots are limited
Come for the science, stay for the ideas, and connect with the people shaping tomorrow’s biotech breakthroughs.
Organised by Galion.exe, Kurma, and Alven, as part of BioWeek Paris.
___
Alven is an independent early-stage venture capital firm with a successful track record of 5 successive funds backing more than 160 startups over 22 years. As of 2022 Alven has over €2b in funds under management.
Brink Therapeutics is developing next-generation recombinases, ultra-precise and efficient enzymes that surpass CRISPR-Cas9.
Galion.exe is a seed-stage venture capital fund investing across Europe and the US, focused on AI infrastructure, AI-powered SaaS, and health technologies. Its portfolio includes companies such as .omics, Alpic, Conception, Contrast, EPICS Biotechnology, Harmattan, Jimini, OneBioscience, Oria Bioscience, PriorLabs, Raidium, and Vaire, reshaping the future of science and technology.
Kurma Partners is a key European venture capital group specialized in healthcare, with €700+ million under management, with two dedicated franchises : Kurma Biofund focused on therapeutic (current active fund KBIII) and Kurma Diagnostics focused on diagnostic and digital health (current active fund Kurma Dx2).
One Biosciences is a precision oncology company that transforms cancer diagnosis through AI-powered single-cell technologies.
PC’up is an accelerator dedicated to deeptech startups entering the scale-up phase. It offers personalized support and on-site facilities tailored to technological development and pre-industrialization, located in Paris’s 5th arrondissement at the ESPCI campus.
Raidium is advancing precision medicine by promoting access to imaging biomarkers through a dedicated AI-native interactive platform. It recently released Curia, a Frontier Foundation Model for 3D Imaging,SOTA in 19 major tasks
WhiteLab Genomics leverages AI-driven computational biology to accelerate genomic medicine development, optimizing therapeutic design and reducing risks.